DeepMed Research

Deciphera Pharmaceuticals, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST

Conditions: GIST - Gastrointestinal Stromal Tumor

First Posted Date: 2019-11-01

Last Posted Date: 2020-05-29

Lead Sponsor: Deciphera Pharmaceuticals, LLC

Registration Number: NCT04148092

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Locally Advanced or Metastatic Solid Tumor

Interventions: Drug: Rebastinib
Drug: Carboplatin

First Posted Date: 2018-10-24

Last Posted Date: 2024-12-27

Lead Sponsor: Deciphera Pharmaceuticals, LLC

Target Recruit Count: 70

Registration Number: NCT03717415

Locations: 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 6 locations

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

Phase 3

Active, not recruiting

Conditions: Gastrointestinal Stromal Tumors

Interventions: Drug: Ripretinib
Drug: Sunitinib

First Posted Date: 2018-09-17

Last Posted Date: 2025-03-05

Lead Sponsor: Deciphera Pharmaceuticals, LLC

Target Recruit Count: 453

Registration Number: NCT03673501

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
🇺🇸
UCLA Hematology Oncology Center - Main Site, Los Angeles, California, United States

and more 117 locations

A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Locally Advanced or Metastatic Solid Tumor

Interventions: Drug: Rebastinib
Drug: Paclitaxel

First Posted Date: 2018-07-26

Last Posted Date: 2024-12-27

Lead Sponsor: Deciphera Pharmaceuticals, LLC

Target Recruit Count: 177

Registration Number: NCT03601897

Locations: 🇺🇸
The University of Kansas Clinical Research Center, Kansas City, Kansas, United States
🇺🇸
Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States

and more 11 locations

Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies

Phase 3

Completed

Conditions: Gastrointestinal Stromal Tumors

Interventions: Drug: DCC-2618
Drug: Placebo Oral Tablet

First Posted Date: 2017-11-27

Last Posted Date: 2022-11-21

Lead Sponsor: Deciphera Pharmaceuticals, LLC

Target Recruit Count: 129

Registration Number: NCT03353753

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
University of Southern California - Norris, Los Angeles, California, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

and more 32 locations

Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

Phase 1

Active, not recruiting

Conditions: Giant Cell Tumor of Tendon Sheath
Tenosynovial Giant Cell Tumor, Diffuse
Advanced Malignant Neoplasm
Tenosynovial Giant Cell Tumor
Pigmented Villonodular Synovitis

Interventions: Drug: Vimseltinib

First Posted Date: 2017-03-03

Last Posted Date: 2024-11-20

Lead Sponsor: Deciphera Pharmaceuticals, LLC

Target Recruit Count: 120

Registration Number: NCT03069469

Locations: 🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸
MSKCC, New York, New York, United States
🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Australia

and more 21 locations

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Advanced Systemic Mastocytosis
Gastrointestinal Stromal Tumors
Advanced Cancers

Interventions: Drug: DCC-2618

First Posted Date: 2015-10-08

Last Posted Date: 2023-12-13

Lead Sponsor: Deciphera Pharmaceuticals, LLC

Target Recruit Count: 282

Registration Number: NCT02571036

Locations: 🇺🇸
Honor Health (GIST, mastocytosis, other solid tumors), Scottsdale, Arizona, United States
🇺🇸
UCLA (glial malignancies only), Los Angeles, California, United States
🇺🇸
Stanford University Hematology Clinic (mastocytosis), Palo Alto, California, United States

and more 23 locations

A Study of DCC-2701 in Participants With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Metastatic Solid Tumors
Cancers With MET Genomic Alterations
Cancers With TRK Genomic Alterations
Locally Advanced Tumors

Interventions: Drug: DCC-2701 tablet

First Posted Date: 2014-08-29

Last Posted Date: 2018-02-01

Lead Sponsor: Deciphera Pharmaceuticals, LLC

Target Recruit Count: 44

Registration Number: NCT02228811

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
The Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 2 locations

Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)

Phase 1

Completed

Conditions: Chronic Myeloid Leukemia

Interventions: Drug: DCC-2036

First Posted Date: 2009-01-22

Last Posted Date: 2014-07-18

Lead Sponsor: Deciphera Pharmaceuticals, LLC

Target Recruit Count: 57

Registration Number: NCT00827138

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇺🇸
Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy